Boswellin Super
Natural health product licensed in Canada
- Licence holder
- Sabinsa Canada Inc.
- NPN or DIN-HM
- 80106073
- Status
- Active licence
- Licence date
- 11 November 2020
- Revision date
- 29 July 2025
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Gum oleoresin Extract : Matériel brut sec Extraction ratio : 14.5:1 Dry plant equivalent : 1,450 mg Potency : 30 % 3-Acetyl-11-keto-beta-boswellic acid | 100 mg | Not calculated |
Non-medicinal ingredients
Hydroxypropylméthylcellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps reduce pain and stiffness associated with osteoarthritis of the knee. Helps to relieve pain associated with osteoarthritis of the knee. Helps to reduce joint pain associated with osteoarthritis of the knee. Helps to relieve joint pain and stiffness associated with osteoarthritis of the knee. Starts to help reduce joint pain and stiffness due to osteoarthritis of knee in as little as 7 days. Supportive therapy for joint pain associated with osteoarthritis of the knee. May help reduce joint pain associated with osteoarthritis of the knee through supporting a healthy inflammatory response. Helps to improve joint function by reducing joint pain in patients with osteoarthritis of the knee.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80106073
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
Has the product changed? Photograph the packaging.